(NASDAQ: MBRX) Moleculin Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Moleculin Biotech's earnings in 2026 is -$41,357,000.On average, 4 Wall Street analysts forecast MBRX's earnings for 2026 to be -$14,072,673, with the lowest MBRX earnings forecast at -$19,936,949, and the highest MBRX earnings forecast at -$7,612,134. On average, 3 Wall Street analysts forecast MBRX's earnings for 2027 to be -$7,103,844, with the lowest MBRX earnings forecast at -$6,825,262, and the highest MBRX earnings forecast at -$7,312,781.
In 2028, MBRX is forecast to generate -$8,765,562 in earnings, with the lowest earnings forecast at -$8,421,814 and the highest earnings forecast at -$9,023,373.